Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Puma Biotechnology (NASDAQ:PBYI) is the #1 top biotech stock out of 642 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 49, which is 26 points higher than the biotech industry average of 23.

PBYI passed 16 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock lose -12.71% over the past year, overperforming other biotech stocks by 55 percentage points.

Puma Biotechnology has an average 1 year price target of $7.00, an upside of 121.52% from Puma Biotechnology's current stock price of $3.16.

Puma Biotechnology stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Ptc Therapeutics (NASDAQ:PTCT) is the #2 top biotech stock out of 642 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ptc Therapeutics (NASDAQ:PTCT) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Ptc Therapeutics (NASDAQ:PTCT) has a Due Diligence Score of 35, which is 12 points higher than the biotech industry average of 23.

PTCT passed 11 out of 33 due diligence checks and has average fundamentals. Ptc Therapeutics has seen its stock return 54.22% over the past year, overperforming other biotech stocks by 122 percentage points.

Ptc Therapeutics has an average 1 year price target of $69.62, an upside of 36.66% from Ptc Therapeutics's current stock price of $50.94.

Ptc Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Ptc Therapeutics, 53.85% have issued a Strong Buy rating, 15.38% have issued a Buy, 23.08% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.

Rigel Pharmaceuticals (NASDAQ:RIGL) is the #3 top biotech stock out of 642 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Rigel Pharmaceuticals (NASDAQ:RIGL) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a Due Diligence Score of 35, which is 12 points higher than the biotech industry average of 23.

RIGL passed 11 out of 33 due diligence checks and has average fundamentals. Rigel Pharmaceuticals has seen its stock return 97.46% over the past year, overperforming other biotech stocks by 165 percentage points.

Rigel Pharmaceuticals has an average 1 year price target of $39.75, an upside of 89.2% from Rigel Pharmaceuticals's current stock price of $21.01.

Rigel Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Rigel Pharmaceuticals, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 7.26%, which is 5 percentage points higher than the biotech industry average of 1.87%.

Dominari Holdings's dividend payout ratio of -7.1% indicates that its high dividend yield might not be sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 3.22%, which is 1 percentage points higher than the biotech industry average of 1.87%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.2% indicates that its dividend yield is sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.75%, which is the same as the biotech industry average of 1.87%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 34.4% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were down -0.35% in the last day, and down -2.52% over the last week. Vyne Therapeutics was the among the top losers in the biotechnology industry, dropping -72.36% yesterday.

VYNE Therapeutics shares are trading lower after the company announced its Phase 2b trial Repibresib Gel in nonsegmental vitiligo did not meet its primary endpoint.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -12.71% in the past year. It has overperformed other stocks in the biotech industry by 55 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 4.75% in the past year. It has overperformed other stocks in the biotech industry by 72 percentage points.

United Therapeutics (NASDAQ:UTHR) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

United Therapeutics has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

United Therapeutics's stock has dropped -16.47% in the past year. It has overperformed other stocks in the biotech industry by 51 percentage points.

53.23% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 101.38% over the next year.

2.11% of biotech stocks have a Zen Rating of A (Strong Buy), 4.23% of biotech stocks are rated B (Buy), 37.42% are rated C (Hold), 35.94% are rated D (Sell), and 20.3% are rated F (Strong Sell).